Ma ssive tum ors ofthe infratemp oral and pterygopalatin e fossa are usually resec ted via the Fisch typ e C infrate mp oral fossa approach. This approach p rovides the su rgeo n with wide eno ugh access to safe ly remove ma ssive tum ors, and it all ows exce llent contro l of the intern al caro tid artery with out leav ing fac ial scars. The disadvantages of this app roac h include a total loss of hearing on the affected side and the risk of dam age to thefacia Inerve. The Fisch type D infratemp oral preauricular approach p rovides a lim ited access to tum ors, but it does preserve hearin g.
Introduction
The four infratemp oral fossa approac hes (types A-D) described by Fisch allow the surge on to remove large tumors without disfigurin g scars .'? The se approac hes provide a con veni ent workin g space and direct access to the lesion , and they obviate the need to enter contaminated areas such as the oropharynx. Th e type A, B, and C approaches (type C is the most frequ entl y perform ed procedure of the three) involve a subtotal petrosectomy, but they all cause an irreve rsible loss of hearin g and Th e type D proc edure is performed by making a preauricular incision and drilling along the floo r of the middle cranial fossa, anterior to the mastoid and the internal carotid artery .P The type D approach doe s not impair hearing or nerve function , but it is limited to tumors no larger than 2.5 em . Lar ger lesions are usually removed via the type C approach.v? All four approac hes hav e been per formed success fully at the University of Zurich over the past 15 yea rs . Anoth er technique of resect ing tumors of the infr atemporal fossa and pterygopalatine fossa-the transfacial, tran smaxilla ry approach-has the disad vantages of access throu gh potentially cont amin ated areas (including the naso-and oropharynx), and a lack of control of the petrous portion ofthe intern al carotid artery .The transfacial approach , how ever, doe s provide good acce ss to the infrat emporal and pterygopalat ine fossae bilaterally.
In light of the benefits and drawback s of the various procedures, we performed a series of nine operations in an attempt to combine the advantages of the type D infratemporal fossa approach and the transfacial , tran smaxiIIary approa ch, while minimizing some of the disadvantages of each .
M ethods
We began the operation with the typ e D approach and switched to the tran sfacial , transmaxillary approach at the appropriate j uncture.
Type D infratemporalfos sa approach. The procedure is begun by positi oning the patient for the infratemporal portion of the operation. Facial nerve monit or leads are placed, and the pati ent is positioned supine, with the head turned to the contralateral side. The type D infratemporal fossa approac h is the mo st anteri or of all the infratemporal fossa approaches . It involves a preauricular inci sion , with a plane of dissection anterior to the middle ear, pet rous hor izont al carotid artery, and eustachian tube. In a fashion similar to the type C approach , the main trunk and frontal 
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Cn
The type D approach provides acces s to the lateral orbital wall , the infratemporal fossa, and the pterygopalatine fossa. This concludes the infratemporal fossa portion of the comb ined approach.
Transfacial, transmaxillary approach. Subsequently, the patient's head is rotated back to the midline, and attention is shifted to the facial area . A large upper buccal sulcus incision is made as wide as possible. On a submucosal plane, the anterior wall of the maxilla bilaterally and the piriform apertures are dissected, and the midface is plane of the hard palate , posteriorl y along the pterygoid plates, and superiorly along the floor of the orbit. When the tumor is confined to the ipsilateral area or when there is a very small extension across the midline into the contralateral maxillary sinus, all the dissection is performed throug h the ipsilateral enlarged maxillotomy. When there is significant tumor on the contra lateral side, a conscious attempt is made to amputate the tumor in the midline, and a second stage is planned to remove the contralateral portion of the tumor. When the tumor has extended into the orbit inferiorly or laterally, the maxillotomy can be extended into an osteotomy of the orbitozygomatic complex , and a wider transfacial approach is created to enter and remove the intraorbital portion of the tumor. At this point, attention is shifted again to the infratemporal fossa wound . Again , with a combination of highspeed drills and microinstruments, the remaining attachments of the tumor are removed under magnific ation by the operative micro scope. The tumor is then delivered through the transfaci al defect ( figure 5 ). The entire tumor is removed through this combined approach.
Occasionally, if there is a cervical extension of the tumor, the type D approach may be combined with a parotid cervical type of incision. Similarly , the type D approach can be combined with a bicoronal incision and a more extensive dissection of the intraorbital contents for tumors with extension into the orbit medially and superiorly. 354 
Results
Over a period of 16 month s, we operated on nine patients (mean age: 52) using a technique that combined the type D infratemporal fos sa appro ach and a tran sfacial, transrnaxillary approach.
The radiologic workup consisted of comp uted tomography and magne tic resonance imaging (figures 6-8). For more information Circle 115 on Reader Service Card static workup; all were negative. Upon present ation, the most common complaint s were dysphagia, sore throat, and an ipsilateral hearin g loss. Less common compl aint s included facial neuralgia, diplopi a, and trismus . Physical findin gs included displacement of the soft palate and tons illar fossa, neck swelling, and ear effusions. Oth er findin gs included cer vical lymph adenopathy, ptosis, diplopia,'? and in one case a hern iation of the tumor through the anterior maxill ary wall. The histopathol ogic distribut ion of the tumors included two neurinomas, two low-grade adenoid cys tic carcinomas, two squamous cell carcinoma s,II one glomus vagale tumor, one pleomorphic adenoma, and one basal cell carcinoma. All nine patients underwent the same surgery. The operative micro scope and the facial nerve monit or were used during every operation . Tumor embolization was performed in six of the nine patient s. Because the intern al carotid artery was not at risk, there was no need for a carotid artery balloon. Gross tumo r remova l was performed in eight of the nine patients; the other patient , who had a massive low-grade adenoid cystic carcinom a, was left with some tumor in the cavernous sinus and around the petrou s portion of the ipsilateral intern al carotid artery .
There was one perioperative cardiopulmonary death . There were no strok es and no permanent facial paral ysis. Paresis of the frontal branch of the facial nerve was noted in two of the nine patients, both of whom recovered in six and nine months, respecti vely. Hearin g was preserved in all nine patients.
Discussion
Although the type D infra temporal fossa approach has the advantage of pre serving hearing, it does not provid e sufficient acce ss for the removal of larger tumors . At the Univ ersity of Zurich, whe re this techn ique was popul arized , surgeons reser ve it for tumors that are no larger than 2.5 cm.2,12 By combining the type D approach with the tran sfacial, transma xillary approac h, we were able to gai n better access to larger tumors while preserving heari ng.
Our com bined approach starts with the type D procedure, which allows dissociation of the posterior and superior margin s of the tumor from the bony skull base, then proceeds to the tran sfacial , transmaxill ary appro ach , which delivers the tumor throu gh a large maxillot omy . Thi s combined two -stage approach not only allow s the rem oval of massive tum ors of the infr atemporal fossa , it grants bilater al access to both the infratemp oral and pterygop alatin e fossae. Because hearing is preser ved, this comb ined approach ca n be used bilaterally for tumors that have progressed beyond the midlin e. 
